Answers are grounded in this paper and cite their sources.
The ANMS GCSI-DD has excellent reliability and validity, supporting its use to assess symptom-based endpoints in gastroparesis clinical studies. Further analyses will be conducted using clinical trial data to ascertain treatment responsiveness and define a responder.
No takes yet. Share an insight, caveat, or question.
Revicki et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: